Johnson & Johnson reports mixed earnings, strong consumer demand  Yahoo FinanceView Full coverage on Google News

www.barrons.com

Johnson & Johnson reports weaker-than-expected Q4 revenue but issues strong guidance for the full year. CFO Joseph Wolk discussed on CNBC.Johnson & Johnson reports weaker-than-expected Q4 revenue but issues strong guidance for the full year. CFO Joseph Wolk discussed on CNBC.

J&J’s upbeat guidance brings good news for big pharma

investingnews.com

investingnews.com

Johnson & Johnson (JNJ) stock is trading higher premarket after the company's Q4 results and an EPS outlook seen above estimates.Q4 adjusted EPS grew +10.3% Y/Y to $2.35, beating...Johnson & Johnson (JNJ) stock is trading higher premarket after the company's Q4 results and an EPS outlook seen above estimates.Q4 adjusted EPS grew +10.3% Y/Y to $2.35, beating...

seekingalpha.com

twitter.com

twitter.com

twitter.com

twitter.com

Check out this infographic breakdown of the company’s fourth- quarter and annual performance.Check out this infographic breakdown of the company’s fourth-quarter and annual performance, with highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Read About Johnson & Johnson's 2022 Fourth-Quarter and Full-Year Earnings

403 Forbidden

www.thederrick.com

404 Not Found

(Reuters) -Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putting the midpoint of the range below Wall Street estimates, while fourth-quarter profit came in ahead of expectations due to cost management and strong demand for some prescription medicines despite lower-than-expected medical device sales. "Given all the macroeconomic uncertainty, geopolitical uncertainty, we thought this was the right approach at this point in time to come out with guidance in the ranges that we did," Chief Financial Officer Joseph Wolk said on a conference call.(Reuters) -Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putting the midpoint of the range below Wall Street estimates, while fourth-quarter profit came in ahead of expectations due to cost management and strong demand for some prescription medicines despite lower-than-expected medical device sales. "Given all the macroeconomic uncertainty, geopolitical uncertainty, we thought this was the right approach at this point in time to come out with guidance in the ranges that we did," Chief Financial Officer Joseph Wolk said on a conference call.

J&J expects inflation, China COVID hit to carry into 2023

www.wsj.com

kdal610.com

Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates.Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates.

J&J Forecasts Strong 2023 Profit On Pharma Boost | Checkout

Johnson & Johnson (JNJ) is set to kick-off pharma earnings season with its Q4 earnings results on Tuesday, January 24th, before market open, amid a challenging macro...Johnson & Johnson (JNJ) is set to kick-off pharma earnings season with its Q4 earnings results on Tuesday, January 24th, before market open, amid a challenging macro...

seekingalpha.com

static.seekingalpha.com